Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Update: Moderna Secures Third Approval In Israel, World Leader In COVID-19 Vaccinations

Plus News From Emergex And AstraZeneca

Executive Summary

Moderna has just secured its third global authorization for its COVID-19 vaccination in Israel, while the European Medicines Agency's review has been delayed.

You may also be interested in...



Moderna Wins EU Approval For COVID-19 Vaccine

The first deliveries of Moderna’s COVID-19 vaccine to European countries are expected to begin next week.

Moderna Increases Minimum Supply Of Coronavirus Vaccine Doses For 2021

The company’s announcement that it would supply at least 600 million doses of mRNA-1273 came as US vaccination rates have fallen far short of expectations.

UK Authorizes ‘Gamechanger’ AstraZeneca Vaccine Despite Data Doubts

UK regulator admits evidence sparse on older patients, but believes longer gap between doses can boost efficacy and accelerate numbers of people immunized.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC143569

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel